FDA Evaluates Illumina GA, 454 for Vaccine QC; Looks to Implement Method for Polio Vaccine
November 16, 2010
FDA Evaluates Illumina GA, 454 for Vaccine QC; Looks to Implement Method for Polio Vaccine
"We believe this is an ultimate tool for monitoring the genetic stability of all viral vaccines — not only live, but also inactivated vaccines," Konstantin Chumakov, associate director for research at the FDA's Office of Vaccines Research and Review, told In Sequence.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Illumina Sees Clinical Applications for MiSeq; Plans FDA Submission in 2012
August 3, 2011 / Clinical Sequencing News - Sequenom Signs Supply Deal for T21 Test with Illumina; Firms to Collaborate on Regulatory Approval
July 12, 2011 / Clinical Sequencing News - Assemblies of E. coli Genome Yield Information Important for Dx Development, Tracing Outbreak
June 14, 2011 / In Sequence - Q&A: Syngenta's Erik Legg on Why Next-Gen Sequencing Is 'Beyond a Trend' in the Ag-bio Industry
November 30, 2010 / In Sequence - Two European Labs Turn to Next-Gen Sequencing for BRCA1/2 Testing
October 26, 2010 / In Sequence